RenovoRx (RNXT) announced its strongest quarterly revenue to date, reporting $563,000 for Q1 2026, a remarkable 136% increase from the previous quarter. This surge in revenue, which accounts for approximately 51% of the company’s total revenue for 2025, is driven by the rapid expansion of its active commercial cancer centers, which have doubled to 16 since the end of 2025, with plans to reach 36 by year-end. The company also has 32 additional centers in various stages of activation, indicating a robust growth pipeline.

The financial results reflect a significant scaling of operations, with a gross profit margin of 85.1% and a solid cash position of $12.4 million following a successful capital raise. Management reiterated its revenue guidance for 2026, targeting between $3 million and $4 million, bolstered by the anticipated conversion of clinical trial sites to commercial status, which is expected to further enhance revenue in the latter half of the year.

For market professionals, RenovoRx’s strong Q1 performance and aggressive expansion strategy underscore its potential for sustained growth in the oncology sector, particularly as it continues to build a network of commercial centers that drive recurring revenue.

Source: fool.com